Expert panel discussion at the Swiss Biotech Day

ProgramPanel discussions

Panel discussions

Moderated debates on the questions shaping biotech.

When
Both conference days, parallel tracks from 14:30 on day one and 09:00 on day two
Where
Rooms Delhi, Kairo, Shanghai 1+2 and Shanghai 3+4, level 0
Format
45 minutes, one moderator and up to four speakers, questions at the end
Who hosts
Sponsors, chapters of the Swiss Biotech Association and partner organizations
Access
Included in the conference pass; switch between parallel tracks freely

About the format

Forty-five-minute panel discussions with one moderator and up to four speakers run in parallel tracks on both days, covering financing, dealmaking, clinical development, regulation, manufacturing and the technologies changing all of them.

Panel discussions are where the conference argues. A sponsor or partner sets the theme, brings a moderator and up to four speakers, and the audience gets to ask questions at the end. Topics in 2026 ranged from policy volatility in pharmaceutical investment to biosimilar commercialization, syndication in early-stage biotech and Swiss-China partnerships.

Panel hosts receive a banner template to introduce their panelists on the holding slide, and every panel discussion is listed with its speakers on the conference website and in the printed conference guide.

Five panelists on stage at the Swiss Biotech Day 2026
A sponsored panel discussion at the Swiss Biotech Day 2026.

Why take part

What panel discussions offer

  1. Thought leadership

    Position your organization on the topic you want to be known for, in front of the whole ecosystem.

  2. Four speakers, one moderator

    Enough voices for a real debate, short enough to keep the room.

  3. Sessions are not recorded

    The Swiss Biotech Day is an in-person event only; what is said in the room stays candid.

Last edition

Panel discussions at the Swiss Biotech Day 2026

See all 2026 panel discussions
  • Monday, 16:30

    What's next in R&D, innovation and clinical development?

    Citeline, a Norstella company

  • Monday, 14:30

    From endpoints to execution: best practices panel

    Clario

  • Monday, 14:30

    Engineering longevity for the future of health

    Deloitte

  • Monday, 14:30

    Building sustainable Swiss–China partnerships

    KPMG

  • Tuesday, 12:15

    Syndication in early-stage biotech: chances and challenges

    BiomedVC

  • Tuesday, 16:00

    Building resilient, value-creating transactions in an unpredictable environment

    Baker McKenzie

Set the agenda in 2027

Panel discussion slots are limited to the number of parallel rooms. Early enquiries get first choice of day and time.